comparemela.com

Latest Breaking News On - Medicinal products - Page 14 : comparemela.com

Idorsia Pharmaceuticals Ltd: Idorsia announces financial results for the first quarter 2024 - advancing the company with renewed vigor

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - May 21, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2024. Business highlights Viatris

United-states
Austria
Macau
Germany
Laos
China
Spain
Mochida
Miyazaki
Japan
Thailand
Taiwan

Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor

Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United-states
Austria
Spain
Laos
China
Germany
Macau
Philippines
Taiwan
Thailand
Mochida
Miyazaki

GNW-Adhoc: Idorsia announces financial results for the first quarter 2024 - advancing the company with renewed vigor

GNW-Adhoc: Idorsia announces financial results for the first quarter 2024 - advancing the company with renewed vigor
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

United-states
Germany
Japan
Northern-ireland
Craigavon
United-kingdom
Allschwil
Switzerland-general
Switzerland
South-korea
France
Spain

PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation

- European Commission decides against adoption of negative opinion - - Translarna authorization remains active in Europe - - 2024 revenue guidance paused - WARREN, N.J., May 20, 2024 /PRNewswire/ .

Brazil
Russia
United-states
Matthewb-klein
Jeanine-clemente
Kylie-okeefe
Linkedin
European-medicines-agency
Twitter
Scientific-advisory-group
European-commission
Facebook

Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Po

NV-387, A Broad-Spectrum Antiviral with Strong Activity Against RSV, Influenza A, Coronaviruses, Others SHELTON, CT / ACCESSWIRE / May 20, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that the strong antiviral activity of N.

United-states
Japan
American
Japanese
Palivizumab-synagis
Securities-exchange
Committee-for-medicinal-products-human
Drug-administration
Theracour-pharma-inc
Exchange-commission
European-medicines-agency
Nanoviricides-inc

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.